NCT05935800

The Effect of the COVID-19 Pandemic on Frailty in Liver Transplant Candidates

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 208 (estimated)
• Sponsor: Methodist Health System · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Frailty is associated with higher rates of morbidity, mortality, and failure to rescue after major surgical procedures \[1\]. Sarcopenia is degenerative loss of skeletal muscle mass and strength. It is a key component of physical frailty and is associated with poorer post-surgical outcomes due to decreased patient strength and vitality.

Detailed description

This study seeks to examine whether the SARS-CoV-2 (COVID-19) pandemic, an ongoing global health crisis that was declared a national emergency by the US Federal Government on March 13, 2020, has exacerbated both frailty and sarcopenia in a population of liver transplant candidates.

Conditions

• Frailty
• Sarcopenia
• COVID-19

Interventions

Type	Name	Description
BEHAVIORAL	COVID Patients who Underwent pre-transplant frailty assessment (PFA) at MDMC	This is a single-center, retrospective study that uses de-identified, anonymized patient data. Data from 369 liver transplant candidates who underwent pre-transplant frailty assessments at the Liver Institute at Methodist Dallas from April 1, 2018 to February 28, 2022. The study data will be divided into cohorts: pre-COVID and COVID. Specifically, the pre-COVID period will consist of the dates between April 1st, 2018 and March 12, 2020, while the COVID period will consist of the dates between March 13, 2020 and February 28th, 2022.

Timeline

• Start date: 2022-04-19
• Primary completion: 2024-04-19
• Completion: 2024-04-19
• First posted: 2023-07-07
• Last updated: 2023-11-15

Locations

1 site across 1 country: United States